Stryker Corporation SYK
Composite 51/100; the shares have moved about 34% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 32/100 — a moderate mark against it.
Growth ranks 64/100 — a moderate point in its favour. Quality ranks 63/100 — a moderate point in its favour. Balance-sheet strength ranks 60/100 — a slight point in its favour.
Momentum ranks 32/100 — a moderate mark against it. Valuation ranks 32/100 — a moderate mark against it. Income ranks 46/100 — a slight mark against it.
What the company does Stryker Corporation (SYK) designs, manufactures, and markets medical technology across MedSurg and Neurotechnology, and Orthopaedics segments. Its portfolio includes surgical robots (e.g., Mako Shoulder), stroke-treatment systems, orthopedic implants, and patient-handling equipment sold globally to hospitals and physicians.
Key financials Stryker’s trailing twelve-month (TTM) margins show strong profitability: gross 65.6%, operating 27.0%, and net 14.4%. Revenue grew 11.2% and EPS grew 9.4% year-over-year. ROE is 16.5% and ROA is 8.2%. Leverage is moderate (Debt/Equity 0.64, Net debt/EBITDA 1.62) with a current ratio of 2.16.
Stock health Stryker’s Sideravia score is 51.6 (average quality, rich valuation, weak momentum). Quality (62.6) and growth (67.2) scores are above average, but valuation (30.7) and momentum (36.6) lag. The stock is down 17.48% over 12 months and 18.01% from its 52-week high, with RSI(14) at 42.80.
Price vs fair value SYK trades at a discount of 18.60% versus the analyst mean target of 382.04. - Recent headlines highlight sector cybersecurity risks and peer underperformance (Boston Scientific cyberattack, IBD, Reuters). - Options traders’ elevated interest suggests uncertainty (Zacks). - Peer comparisons (ISRG, BSX) are cited as valuation caution (Trefis).
Looking forward Forward P/E of 22.99 and PEG of 0.41 suggest earnings growth may not yet be fully priced in, but momentum remains weak. Analysts’ mean target implies 18.60% upside from the current price of 322.12.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.